Environmental Enteric Dysfunction, Stunting
Conditions
Keywords
probiotic, microbiome, pregnant women, capscan device, urine LR, vivomixx, pakistan, malnourished children, biomarkers, EED
Brief summary
There is an urgent need to identify interventions that can improve the supportive uterine environment in which the fetus establishes his/her growth. Investigators believe that this necessitates improving the delivery of nutrients to the mother, and in turn that requires a healthy microbiota. Reducing intestinal inflammation will also have a profound impact on maternal and fetal immunity, though there is limited information on the impact of maternal health on placental function. This trial will determine if a well-established probiotic, Vivomixx, can modulate the maternal microbiota and ameliorate the maternal environmental enteropathy which compromises growth in the first 1000 days. This trial is the first in a proposed series of proof-of-concept intervention studies that are intended to provide data to enable a rational selection of interventions to be evaluated at scale in future large-scale trials. This initial study will also serve the purpose of developing a harmonized multi-site Experimental Medicine Platform across four countries (Bangladesh, Pakistan, Senegal, Zambia). Harmonized procedures will develop the capacity to deliver high-quality trials for the evaluation of potential interventions to improve maternal nutritional status and growth in utero. To this end, measuring and understanding variability in endpoint measurements is a key deliverable.
Detailed description
76 healthy pregnant women in their second trimester will be enrolled and will be randomized to receive either probiotic or placebo for 8 weeks. It will be a double-blind trial. Pregnant women will be recruited in the community through demographic surveillance system established in Matiari, Pakistan. The study staff will approach the potential participants and will introduce them to this study. If Participants agree, a screening consent form will be taken in which investigators will assess them clinically and will measure their hemoglobin level and gestational ultrasound for confirmation of their trimester/gestational weeks. Based on the screening results and clinical staff assessment, women will be enrolled after taking trial participation consent. Once the participant is enrolled, investigators will collect blood, urine LR, and stool samples (flash frozen and CapScan) before giving either a placebo or probiotic(which will be replenished after every 3 days). investigators will then follow them weekly for compliance and adverse event data collection for 56 days (8 weeks). investigators will again collect the same blood and stool samples after completion of 56 days. An additional visit at 36 weeks will be done to record weight and for a gestational ultrasound. Pregnancy outcomes will be recorded and then the child will be followed at 3,6,9 and 12 weeks for anthropometry and morbidity data collection. Gestational ultrasounds will be performed at screening at 20, 28 and 36 weeks of gestation.
Interventions
DRUGVivomixx
Vivomixx (a mixture of Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subspecies bulgaricus, Streptococcus salivarius subspecies thermophiles, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), as VivomixxAll consenting participants will be randomized into the treatment to control arm, receiving either Vivomixx or a placebo for 8 weeks. During the study, women will visit the healthcare center or vice-versa on a bi-weekly basis to receive sachets of Vivomixx or a placebo according to their trial arm.
DEVICECapScan®
The only non-standard sample collection instrument is the CapScan device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples.
Sponsors
Bill and Melinda Gates Foundation
International Centre for Diarrhoeal Disease Research, Bangladesh
University of Zambia
Institut Pasteur de Dakar
Aga Khan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Randomisation will be carried out using sealed envelopes, using a randomisation code prepared by the trial statistician, which will be stratified by study centre. Each woman who gives consent will be given a trial identification (TID) number which will match the number on the randomisation envelopes. The trial will be blinded with an identical placebo (microcrystalline cellulose, prepared by Mendes SA, Lugano). Samples will be run and analysed using TID only, with all data cleaning and re-assays carried out blinded. The trial statistician will unblind lab data once databases are finalised.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
No
Inclusion criteria
* Women over the age of 18 in their second trimester of pregnancy living in defined geographical areas of Matiari, where it can be assumed that environmental enteropathy is universal.
Exclusion criteria
* have had diarrhoea, defined as the passage of three or more loose stools per 24 hours, in the preceding 14 days; * have taken antibiotics or probiotics in the preceding 14 days; * have taken non-steroidal anti-inflammatory drugs or steroids in the preceding 14 days; * have haemoglobin concentration \<8g/dl; * have any illness which in the opinion of the investigator will complicate assessment of safety or efficacy; * have any gastrointestinal contraindication to ingestion of a capsule (known or suspected gastrointestinal obstruction, stricture, fistula, gastroparesis, or any swallowing disorder); * have a plan to leave the study area within the follow-up period; but may be enrolled if/when these disqualifiers have expired.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in inflammation and epithelial damage in pregnant women with environmental enteropathy | Day 0 (screening) - Day 56 | Percentage change (mean, unweighted) in a multiple panels of biomarkers between baseline and last sample collected after 56 days of treatment, compared to a control group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vivomixx Reduction in permeability | Day 1 - Day 56 | Reduction in LR ratio in Vivomixx compared to placebo groups |
| Impact of the host metabolome in pregnant woman | Day 1 - Day 56 | Change in the metabolome, Untargeted urine, and plasma (and fecal) metabolome before and after the intervention. |
| Rate of weight gain in the 2nd trimester of pregnancy | Day 1 - Day 56 | Weight gain velocity in the 2nd trimester of pregnancy |
| Variability in endpoints across geographies and participating laboratories | Day 1 - Day 56 | Measurements of variability, including standard deviations and kappa values; Preliminary work across all sites using identical kits and harmonised SOPs |
| Reduction in enteropathogen colonisation | Day 1 - Day 56 | Reduction in colonisation with specific enteropathogens (Salmonella, Shigella, Campylobacter, ETEC, EPEC, EAEC, rotavirus, norovirus, Giardia and Cryptosporidium), by qPCR, between baseline and last sample collected after 56 days of treatment, in Vivomixx compared to placebo groups |
| Impact of Vivomixx on the structure and function of the microbiome | Day 1 - Day 56 | Change in relative abundance values of alpha and beta diversity pre- and post-treatment samples. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Impact of Vivomixx on intra-uterine growth restriction velocity | Day 1 - 161 Days | Ultrasound evaluation of intrauterine growth. |
| CapScan success rate in delivering an assessment of the microbiome throughout the gut | Day 1 - Day 56 | Recovery of useful data from CapScan; completion of whole gut microbiome profiles |
| Impact on growth of the infant | Day 189 - Day 554 | Growth of infant during first year by measuring WHZ score on quarterly basis |
Countries
Pakistan
Outcome results
None listed